SPRB
NASDAQ
US
Spruce Biosciences, Inc. - Common Stock
$70.50
▲ +$0.97
(+1.39%)
Vol 38K
4
Quality Score
fail
Rev ✗
NI ✗
>IPO ✗
Mkt Cap
$93.2M
ROE
-305.4%
Margin
-1079.9%
D/E
10.01
Beta
15.15
52W
$4–$675
Wall Street Consensus
10 analysts · Apr 20264
Strong Buy
5
Buy
1
Hold
0
Sell
0
Strong Sell
90.0%
Buy Rating
Price Chart
Similar Stocks
KPTI
Karyopharm Therapeutics Inc
$125.5M
CRDF
Cardiff Oncology Inc
$189.3M
CADL
Candel Therapeutics Inc
$310.2M
ALDX
Aldeyra Therapeutics Inc
$99.9M
COYA
Coya Therapeutics Inc
$121.4M
QTTB
Q32 Bio Inc
$40.9M
PYXS
Pyxis Oncology Inc
$71.6M
RCEL
AVITA Medical Inc
$105.2M
MCRB
Seres Therapeutics Inc
P/E 25.0
$134.6M
Earnings
Beat rate: 20.0%| Quarter | EPS Est | EPS Act | Surprise |
|---|---|---|---|
| Dec 2025 | $-8.15 | $-11.28 | $-3.13 |
| Sep 2025 | $-14.21 | $-14.58 | $-0.37 |
| Jun 2025 | $-19.51 | $-3.50 | +$16.01 |
| Mar 2025 | $-16.42 | $-24.00 | $-7.58 |
Fundamentals Trend
| Metric | 2025-03-31 | 2025-06-30 | 2025-10-02 | 2025-11-03 | 2025-12-03 | 2026-01-02 |
|---|---|---|---|---|---|---|
| ROE (TTM) | -143.2% | -177.4% | -177.4% | -177.4% | -177.4% | -305.4% |
| P/E (TTM) | — | — | — | — | — | — |
| Net Margin | — | — | -1079.9% | -1079.9% | -1079.9% | -1079.9% |
| Gross Margin | — | — | — | — | — | — |
| D/E Ratio | 8.78 | 7.15 | 7.15 | 7.15 | 7.15 | 10.01 |
| Current Ratio | 1.95 | 2.60 | 2.60 | 2.60 | 2.60 | 1.54 |
Key Ratios
ROA (TTM)
-168.0%
P/S (TTM)
18.99
P/B
0.6
EPS (TTM)
$-84.64
CF/Share
$-1.43
52W High
$675.00
52W Low
$4.28
$4.28
52-Week Range
$675.00
How does SPRB compare to Biotechnology peers?
Peer group: Micro-cap Biotechnology (All) · 528 companies
SPRB valuation vs Biotechnology peers
P/E ratio
—
▼
0%
below
peers
(18.8)
vs Peers
vs Industry
Undervalued
P/S ratio
19.0
▲
48%
above
peers
(12.9)
vs Peers
vs Industry
Pricier
P/B ratio
0.6
▼
76%
below
peers
(2.5)
vs Peers
vs Industry
Undervalued
Div yield
—
▼
0%
below
peers
(0.0%)
vs Peers
vs Industry
Low yield
SPRB profitability vs Biotechnology peers
ROE
-305.4%
▼
354%
below
peers
(-67.3%)
vs Peers
vs Industry
Weak
Net margin
-1079.9%
▼
277%
below
peers
(-286.8%)
vs Peers
vs Industry
Weak
Gross margin
—
▼
0%
below
peers
(78.6%)
vs Peers
vs Industry
In line
ROA
-168.0%
▼
260%
below
peers
(-46.7%)
vs Peers
vs Industry
Weak
SPRB financial health vs Biotechnology peers
D/E ratio
10.0
▼
0%
below
peers
(0.0)
vs Peers
vs Industry
High debt
Current ratio
1.5
▼
65%
below
peers
(4.4)
vs Peers
vs Industry
Low liquidity
Beta
15.2
▲
1461%
above
peers
(1.0)
vs Peers
vs Industry
More volatile
SPRB fundamentals radar
SPRB
Peer median
Industry
SPRB profitability vs leverage
Bubble size = market cap · X = net margin · Y = D/E ratio